170 related articles for article (PubMed ID: 36297673)
1. A ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Mantle Cell Lymphoma (MCL) Cells.
Ghaderi A; Zhong W; Okhovat MA; Aschan J; Svensson A; Sander B; Schultz J; Olin T; Österborg A; Hojjat-Farsangi M; Mellstedt H
Pharmaceutics; 2022 Oct; 14(10):. PubMed ID: 36297673
[TBL] [Abstract][Full Text] [Related]
2. ROR1 Is Expressed in Diffuse Large B-Cell Lymphoma (DLBCL) and a Small Molecule Inhibitor of ROR1 (KAN0441571C) Induced Apoptosis of Lymphoma Cells.
Ghaderi A; Daneshmanesh AH; Moshfegh A; Kokhaei P; Vågberg J; Schultz J; Olin T; Harrysson S; Smedby KE; Drakos E; Rassidakis GZ; Österborg A; Hojjat-Farsangi M; Mellstedt H
Biomedicines; 2020 Jun; 8(6):. PubMed ID: 32586008
[TBL] [Abstract][Full Text] [Related]
3. A Small Molecule Targeting the Intracellular Tyrosine Kinase Domain of ROR1 (KAN0441571C) Induced Significant Apoptosis of Non-Small Cell Lung Cancer (NSCLC) Cells.
Ghaderi A; Okhovat MA; Lehto J; De Petris L; Manouchehri Doulabi E; Kokhaei P; Zhong W; Rassidakis GZ; Drakos E; Moshfegh A; Schultz J; Olin T; Österborg A; Mellstedt H; Hojjat-Farsangi M
Pharmaceutics; 2023 Apr; 15(4):. PubMed ID: 37111634
[TBL] [Abstract][Full Text] [Related]
4. A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of ibrutinib-resistant ROR1
Ghaderi A; Okhovat MA; Wikanthi LSS; Svensson A; Palma M; Schultz J; Olin T; Österborg A; Mellstedt H; Hojjat-Farsangi M
EJHaem; 2021 Aug; 2(3):498-502. PubMed ID: 35844694
[TBL] [Abstract][Full Text] [Related]
5. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
Li J; Wang X; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Pan Z; Ding N; Song Y; Zhu J
Int J Cancer; 2018 Jan; 142(1):202-213. PubMed ID: 28905990
[TBL] [Abstract][Full Text] [Related]
6. Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma.
Karvonen H; Chiron D; Niininen W; Ek S; Jerkeman M; Moradi E; Nykter M; Heckman CA; Kallioniemi O; Murumägi A; Ungureanu D
Blood Adv; 2017 Nov; 1(24):2257-2268. PubMed ID: 29296874
[TBL] [Abstract][Full Text] [Related]
7. Predicting ROR1/BCL2 combination targeted therapy of small cell carcinoma of the lung.
Wang WZ; Shilo K; Amann JM; Shulman A; Hojjat-Farsangi M; Mellstedt H; Schultz J; Croce CM; Carbone DP
Cell Death Dis; 2021 Jun; 12(6):577. PubMed ID: 34088900
[TBL] [Abstract][Full Text] [Related]
8. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma.
Jiang VC; Liu Y; Jordan A; McIntosh J; Li Y; Che Y; Jessen KA; Lannutti BJ; Wang M
J Hematol Oncol; 2021 Aug; 14(1):132. PubMed ID: 34454548
[TBL] [Abstract][Full Text] [Related]
9. Targeting the Receptor Tyrosine Kinase ROR1 by Small Molecules.
Hojjat-Farsangi M; Moshfegh A; Schultz J; Norin M; Olin T; Österborg A; Mellstedt H
Handb Exp Pharmacol; 2021; 269():75-99. PubMed ID: 34490515
[TBL] [Abstract][Full Text] [Related]
10. A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib.
Daneshmanesh AH; Hojjat-Farsangi M; Ghaderi A; Moshfegh A; Hansson L; Schultz J; Vågberg J; Byström S; Olsson E; Olin T; Österborg A; Mellstedt H
PLoS One; 2018; 13(6):e0198038. PubMed ID: 29856777
[TBL] [Abstract][Full Text] [Related]
11. Synergistic Cytotoxicity of Bendamustine and the BTK Inhibitor in a Mantle Cell Lymphoma Cell Line.
Hagiwara K; Tokunaga T; Iida H; Nagai H
Anticancer Res; 2015 Dec; 35(12):6679-84. PubMed ID: 26637884
[TBL] [Abstract][Full Text] [Related]
12. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis.
Cinar M; Hamedani F; Mo Z; Cinar B; Amin HM; Alkan S
Leuk Res; 2013 Oct; 37(10):1271-7. PubMed ID: 23962569
[TBL] [Abstract][Full Text] [Related]
13. Receptor tyrosine kinase-like orphan receptor 1 inhibitor strictinin exhibits anti-cancer properties against highly aggressive androgen-independent prostate cancer.
Sivaganesh V; Peethambaran B
Explor Target Antitumor Ther; 2023; 4(6):1188-1209. PubMed ID: 38213538
[TBL] [Abstract][Full Text] [Related]
14. Promising efficacy of novel BTK inhibitor AC0010 in mantle cell lymphoma.
Yan X; Zhou Y; Huang S; Li X; Yu M; Huang J; Wang J; Ma Z; Jin J; Pan J; Li C; Li F; Jin J
J Cancer Res Clin Oncol; 2018 Apr; 144(4):697-706. PubMed ID: 29392403
[TBL] [Abstract][Full Text] [Related]
15. Protein Kinase CK2 represents a new target to boost Ibrutinib and Venetoclax induced cytotoxicity in mantle cell lymphoma.
Manni S; Pesavento M; Spinello Z; Saggin L; Arjomand A; Fregnani A; Quotti Tubi L; Scapinello G; Gurrieri C; Semenzato G; Trentin L; Piazza F
Front Cell Dev Biol; 2022; 10():935023. PubMed ID: 36035991
[TBL] [Abstract][Full Text] [Related]
16. Targeting malignant B cells with an immunotoxin against ROR1.
Baskar S; Wiestner A; Wilson WH; Pastan I; Rader C
MAbs; 2012; 4(3):349-61. PubMed ID: 22531447
[TBL] [Abstract][Full Text] [Related]
17. Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma.
Rosich L; Xargay-Torrent S; López-Guerra M; Campo E; Colomer D; Roué G
Clin Cancer Res; 2012 Oct; 18(19):5278-89. PubMed ID: 22879389
[TBL] [Abstract][Full Text] [Related]
18. Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia.
Yi X; Jain N; Iles LR; Ayres ML; Wierda WG; Gandhi V
Front Oncol; 2022; 12():833714. PubMed ID: 35273915
[TBL] [Abstract][Full Text] [Related]
19. Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma.
Dengler MA; Teh CE; Thijssen R; Gangoda L; Lan P; Herold MJ; Gray DH; Kelly GL; Roberts AW; Adams JM
Oncogene; 2020 Feb; 39(9):2009-2023. PubMed ID: 31772331
[TBL] [Abstract][Full Text] [Related]
20. Long non-coding RNA profile in mantle cell lymphoma identifies a functional lncRNA ROR1-AS1 associated with EZH2/PRC2 complex.
Hu G; Gupta SK; Troska TP; Nair A; Gupta M
Oncotarget; 2017 Oct; 8(46):80223-80234. PubMed ID: 29113297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
